Immune checkpoint protein development is crucial for modulating immune responses in cancer immunotherapy. These proteins regulate T-cell activation, preventing excessive immune reactions while enhancing tumor-targeting therapies. Advanced techniques, including stable cell line development and protein labeling, improve precision and therapeutic efficacy. By optimizing immune checkpoint proteins, researchers can develop next-generation treatments, ensuring effective immune modulation and enhanced therapeutic outcomes.